1. Home
  2. FINV vs SLDB Comparison

FINV vs SLDB Comparison

Compare FINV & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinVolution Group

FINV

FinVolution Group

N/A

Current Price

$4.47

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$9.03

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FINV
SLDB
Founded
2007
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
FINV
SLDB
Price
$4.47
$9.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
11
Target Price
$12.10
$16.36
AVG Volume (30 Days)
385.5K
970.1K
Earning Date
05-19-2026
05-12-2026
Dividend Yield
6.09%
N/A
EPS Growth
N/A
34.97
EPS
N/A
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.58
N/A
P/E Ratio
$3.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$3.79
52 Week High
$9.73
$11.45

Technical Indicators

Market Signals
Indicator
FINV
SLDB
Relative Strength Index (RSI) 34.66 56.34
Support Level $4.35 $6.25
Resistance Level $5.07 $11.45
Average True Range (ATR) 0.14 0.45
MACD -0.04 0.07
Stochastic Oscillator 5.22 95.89

Price Performance

Historical Comparison
FINV
SLDB

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: